% IMPORTANT: The following is UTF-8 encoded. This means that in the presence % of non-ASCII characters, it will not work with BibTeX 0.99 or older. % Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or % “biber”. @ARTICLE{Bakas:1032187, author = {Bakas, Spyridon and Vollmuth, Philipp and Galldiks, Norbert and Booth, Thomas C and Aerts, Hugo J W L and Bi, Wenya Linda and Wiestler, Benedikt and Tiwari, Pallavi and Pati, Sarthak and Baid, Ujjwal and Calabrese, Evan and Lohmann, Philipp and Nowosielski, Martha and Jain, Rajan and Colen, Rivka and Ismail, Marwa and Rasool, Ghulam and Lupo, Janine M and Akbari, Hamed and Tonn, Joerg C and Macdonald, David and Vogelbaum, Michael and Chang, Susan M and Davatzikos, Christos and Villanueva-Meyer, Javier E and Huang, Raymond Y}, title = {{A}rtificial {I}ntelligence for {R}esponse {A}ssessment in {N}euro {O}ncology ({AI}-{RANO}), part 2: recommendations for standardisation, validation, and good clinical practice}, journal = {The lancet / Oncology}, volume = {25}, number = {11}, issn = {1470-2045}, address = {London}, publisher = {The Lancet Publ. Group}, reportid = {FZJ-2024-06056}, pages = {e589 - e601}, year = {2024}, abstract = {Technological advancements have enabled the extended investigation, development, and application of computational approaches in various domains, including health care. A burgeoning number of diagnostic, predictive, prognostic, and monitoring biomarkers are continuously being explored to improve clinical decision making in neuro-oncology. These advancements describe the increasing incorporation of artificial intelligence (AI) algorithms, including the use of radiomics. However, the broad applicability and clinical translation of AI are restricted by concerns about generalisability, reproducibility, scalability, and validation. This Policy Review intends to serve as the leading resource of recommendations for the standardisation and good clinical practice of AI approaches in health care, particularly in neuro-oncology. To this end, we investigate the repeatability, reproducibility, and stability of AI in response assessment in neuro-oncology in studies on factors affecting such computational approaches, and in publicly available open-source data and computational software tools facilitating these goals. The pathway for standardisation and validation of these approaches is discussed with the view of trustworthy AI enabling the next generation of clinical trials. We conclude with an outlook on the future of AI-enabled neuro-oncology.}, cin = {INM-4 / INM-3}, ddc = {610}, cid = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-3-20090406}, pnm = {5253 - Neuroimaging (POF4-525) / 5252 - Brain Dysfunction and Plasticity (POF4-525)}, pid = {G:(DE-HGF)POF4-5253 / G:(DE-HGF)POF4-5252}, typ = {PUB:(DE-HGF)16}, pubmed = {39481415}, UT = {WOS:001348280600001}, doi = {10.1016/S1470-2045(24)00315-2}, url = {https://juser.fz-juelich.de/record/1032187}, }